Key Points
- CFO Dominic Piscitelli sold 14,000 Oric Pharmaceuticals shares at an average price of $13.53, generating $189,420. The Rule 10b5-1 transaction reduced his direct ownership by 16.7% to 69,828 shares.
- Oric shares opened at $13.85, with a 52-week range of $7.23 to $14.68. The company reported quarterly EPS of $(0.38), missing analyst expectations of $(0.36).
- Wall Street’s outlook remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $21.17, despite one sell rating. Institutional investors own approximately 95.05% of the stock.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 14,000 shares of the stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dominic Piscitelli also recently made the following trade(s):
- On Monday, September 28th, Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.53, for a total value of $181,302.00.
- On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total value of $8,100.00.
- On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00.
Oric Pharmaceuticals Stock Performance
Oric Pharmaceuticals stock opened at $13.85 on Thursday. The company has a 50-day simple moving average of $12.94 and a 200-day simple moving average of $10.98. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.68.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.02). On average, research analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oric Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in Oric Pharmaceuticals in the second quarter worth about $899,000. Engineers Gate Manager LP bought a new position in Oric Pharmaceuticals in the 2nd quarter valued at about $694,000. Integrated Wealth Concepts LLC acquired a new position in Oric Pharmaceuticals during the 2nd quarter valued at about $38,000. Squarepoint Ops LLC acquired a new position in Oric Pharmaceuticals during the 2nd quarter valued at about $3,729,000. Finally, AXQ Capital LP acquired a new position in Oric Pharmaceuticals during the 2nd quarter valued at about $396,000. 95.05% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
ORIC has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, July 25th. BTIG Research initiated coverage on Oric Pharmaceuticals in a report on Wednesday, September 23rd. They issued a "buy" rating and a $26.00 price objective for the company. HC Wainwright raised their target price on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Finally, Leerink Partners began coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They issued an "outperform" rating and a $26.00 target price on the stock. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.17.
View Our Latest Research Report on ORIC
About Oric Pharmaceuticals
(
Get Free Report)
Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.
Oric's pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
